Literature DB >> 15994418

Establishment of a cell line derived from a canine prostate carcinoma with a highly rearranged karyotype.

S Winkler1, H Murua Escobar, N Eberle, N Reimann-Berg, I Nolte, J Bullerdiek.   

Abstract

Akin to the situation in humans, dogs are frequently affected by tumors of the prostate. The malignancies share many similarities between both species, for example, median age at the onset of the disease and metastatic behavior. In human prostatic tumor samples, investigations of prepared metaphase spreads showed a variety of chromosomal aberrations, with trisomies of chromosomes 7, 8, and 17 as the leading cytogenetic abnormalities. In this article we present one case of a canine adenocarcinoma of the prostate, including clinical examination and establishment of a cell line from a tumor sample obtained from the affected 10-year-old male Briard. Searching for similarities between both species in respect to chromosomal changes within the tumor samples, we investigated prepared metaphases of the canine cell line cytogenetically. These investigations presented a highly rearranged karyotype showing a large biarmed marker consisting of material from chromosomes 1 and 2 in addition to centromeric fusions between dog chromosomes 1 and 5 that both could be identified in every metaphase investigated, while centric fusions of chromosomes 4 and 5 occurred in up to 50% of the metaphases. The cell line grew very well and showed evidence of being spontaneously immortalized when it crossed the 20th passage.

Entities:  

Mesh:

Year:  2005        PMID: 15994418     DOI: 10.1093/jhered/esi085

Source DB:  PubMed          Journal:  J Hered        ISSN: 0022-1503            Impact factor:   2.645


  11 in total

1.  Longitudinal MRI contrast enhanced monitoring of early tumour development with manganese chloride (MnCl2) and superparamagnetic iron oxide nanoparticles (SPIOs) in a CT1258 based in vivo model of prostate cancer.

Authors:  Katharina A Sterenczak; Martin Meier; Silke Glage; Matthias Meyer; Saskia Willenbrock; Patrick Wefstaedt; Martina Dorsch; Jörn Bullerdiek; Hugo Murua Escobar; Hans Hedrich; Ingo Nolte
Journal:  BMC Cancer       Date:  2012-07-11       Impact factor: 4.430

2.  Characterization of nanoparticle mediated laser transfection by femtosecond laser pulses for applications in molecular medicine.

Authors:  Markus Schomaker; Dag Heinemann; Stefan Kalies; Saskia Willenbrock; Siegfried Wagner; Ingo Nolte; Tammo Ripken; Hugo Murua Escobar; Heiko Meyer; Alexander Heisterkamp
Journal:  J Nanobiotechnology       Date:  2015-02-03       Impact factor: 10.435

3.  Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis.

Authors:  Eva-Maria Packeiser; Marion Hewicker-Trautwein; Heike Thiemeyer; Annika Mohr; Johannes Junginger; Jan Torben Schille; Hugo Murua Escobar; Ingo Nolte
Journal:  PLoS One       Date:  2020-03-13       Impact factor: 3.240

4.  Establishment and characterization of stable red, far-red (fR) and near infra-red (NIR) transfected canine prostate cancer cell lines.

Authors:  Wen Liu; Sina Sender; Weibo Kong; Julia Beck; Anett Sekora; Kirsten Bornemann-Kolatzki; Ekkehart Schuetz; Christian Junghanss; Bertram Brenig; Ingo Nolte; Hugo Murua Escobar
Journal:  Cancer Cell Int       Date:  2020-04-29       Impact factor: 5.722

5.  Isoquinolinamine FX-9 Exhibits Anti-Mitotic Activity in Human and Canine Prostate Carcinoma Cell Lines.

Authors:  Jan Torben Schille; Ingo Nolte; Eva-Maria Packeiser; Laura Wiesner; Jens Ingo Hein; Franziska Weiner; Xiao-Feng Wu; Matthias Beller; Christian Junghanss; Hugo Murua Escobar
Journal:  Int J Mol Sci       Date:  2019-11-07       Impact factor: 5.923

6.  PDA Indolylmaleimides Induce Anti-Tumor Effects in Prostate Carcinoma Cell Lines Through Mitotic Death.

Authors:  Jan Torben Schille; Ingo Nolte; Julia Beck; Daria Jilani; Catrin Roolf; Anahit Pews-Davtyan; Arndt Rolfs; Larissa Henze; Matthias Beller; Bertram Brenig; Christian Junghanss; Ekkehard Schütz; Hugo Murua Escobar
Journal:  Front Vet Sci       Date:  2021-01-20

7.  Evaluation of combination protocols of the chemotherapeutic agent FX-9 with azacitidine, dichloroacetic acid, doxorubicin or carboplatin on prostate carcinoma cell lines.

Authors:  Franziska Weiner; Jan Torben Schille; Jens Ingo Hein; Xiao-Feng Wu; Matthias Beller; Christian Junghanß; Hugo Murua Escobar; Ingo Nolte
Journal:  PLoS One       Date:  2021-08-25       Impact factor: 3.240

8.  Establishing an in vivo model of canine prostate carcinoma using the new cell line CT1258.

Authors:  Melani A M Fork; Hugo Murua Escobar; Jan T Soller; Katharina A Sterenczak; Saskia Willenbrock; Susanne Winkler; Martina Dorsch; Nicola Reimann-Berg; Hans J Hedrich; Jörn Bullerdiek; Ingo Nolte
Journal:  BMC Cancer       Date:  2008-08-15       Impact factor: 4.430

9.  Generation and characterisation of a canine EGFP-HMGA2 prostate cancer in vitro model.

Authors:  Saskia Willenbrock; Siegfried Wagner; Nicola Reimann-Berg; Mohammed Moulay; Marion Hewicker-Trautwein; Ingo Nolte; Hugo Murua Escobar
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

10.  Metformin and sodium dichloroacetate effects on proliferation, apoptosis, and metabolic activity tested alone and in combination in a canine prostate and a bladder cancer cell line.

Authors:  Katharina Klose; Eva-Maria Packeiser; Petra Müller; José Luis Granados-Soler; Jan Torben Schille; Sandra Goericke-Pesch; Manfred Kietzmann; Hugo Murua Escobar; Ingo Nolte
Journal:  PLoS One       Date:  2021-09-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.